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Abbreviations. 
3-AB, 3-aminobenzamide; AP-1, activator protein 1; COX-2, cyclooxygenase 2; ELAM, 
endothelial leukocyte cell adhesion molecule; ERK, extracellular signal-regulated kinase; 
HMG, high mobility group; 4-HQN, 4-hydroxyquinazoline; ICAM, intercellular adhesion 
molecule; JNK, c-Jun N-terminal kinase; LPS, lipopolysaccharide; MAP, mitogen activated 
protein; MRI, magnetic resonance imaging; NF-κB, nuclear factor kappa B; p90RSK, protein 
of 90 kDa from the ribosomal subunit S6 kinase; PARP, poly-(ADP-ribose) polymerase; PI3, 
phosphatidylinositol 3; PMNs, peripheral blood mononuclear cells; ROS, reactive oxygen 
species; TNF-α, tumor necrosis factor α. 
 3
Introduction. 
 
Sepsis and septic shock 
Sepsis describes a complex clinical syndrome that results from a harmful or damaging host 
response to infection. Many of the components of the innate immune response that are 
normally concerned with host defences against infection can, under some circumstances, 
cause cell and tissue damage and hence multiple organ failure, the clinical hallmark of sepsis. 
Sepsis develops when the initial, appropriate host response to an infection becomes amplified, 
and then dysregulated. Clinically, the onset is often insidious: features may include fever, 
mental confusion, transient hypotension, tachycardia, tachypnea, leukocytosis, diminished 
urine output or unexplained thrombocytopenia. If untreated, the patient may develop 
respiratory or renal failure, abnormalities of coagulation and profound and unresponsive 
hypotension.  
During the oneset of sepsis, the inflammatory system becomes hyperactive, involving 
both cellular and humoral defense mechanisms. Endothelial and epithelial cells, as well as 
neutrophils, macrophages and lymphocytes, produce powerful pro-inflammatory mediators, 
especially tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, IL-1 and IL-8. 
Simultaneously, robust production of acute-phase proteins, such as C-reactive protein, occurs 
and humoral defense mechanisms such as the complement system are activated, resulting in 
production of pro-inflammatory mediators, including C5a, the complement split product. C5a 
ultimately enhances cytokine and chemokine production. Furthermore, the coagulation system 
becomes activated through various mechanisms, often resulting in disseminated intavascular 
coagulopathy. The described mediators are produced early in the oneset of sepsis and reflect 
the overactive status of the inflammatory response. Phagocytic cells (neutrophils and 
macrophages) respond to many of these mediators by releasing granular enzymes and 
 4
producing reactive oxygen species (ROS) such as H2O2, which is a crucial product for the 
killing of bacteria. H2O2 is also capable of causing tissue damage, which ultimately leads to 
increased vascular permeability and organ injury. In later stages of sepsis, anti-inflammatory 
mediators are produced (such as IL-10, transforming growth factor-β and IL-13), leading to 
abatement in the production of many of the pro-inflammatory mediators. In this phase, 
various innate functions are supressed, especially the functions of neutrophils, leading to a 
hyporeactive host defense system and immunoparalysis. 
The „public enemy”: LPS 
The commonest sites of infection are the lungs, abdominal cavity, the urinary tract and the 
primary infections of the blood stream and it appears often as a result of a systemic Gram-
negative bacterial infection. Determining the structural components of bacteria that are 
responsible for initiating the septic process has been important not only in understanding the 
underlying mechanisms, but also in identifying potential therapeutic targets.  
In Gram-negative bacteria, lipopolysaccharide (LPS; known also as endotoxin) has a 
dominant role (Fig. 1). The outer membrane of Gram-negative bacteria is constructed of a 
lipid bilayer, separeted from the inner cytoplasmic membrane by peptidoglycan.  
 
 
 
 
 
 
 
 
Fig. 1 The stucture of lipopolysaccharide. 
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The LPS molecule is embedded in the outer membrane and the lipid A portion of the 
molecule serves to anchor LPS in the bacterial cell wall. Biophysical studies on the three 
dimensional conformation adopted by different lipid A partial structures have revealed that, 
under physiological conditions, the most active forms assume the shape of a truncated cone, 
whereas inactive molecules prefer a lamellar structure and become progressively more 
cylindrical. These conformational changes seem to correlate with the ability to activate host 
cell membranes. There is no endotoxin in Gram-positive bacteria, but their cell walls do 
contain peptidoglycan and lipoteichoic acid, and several investigators have identified 
structural components that account their biological activity. Both peptidoglycan and 
lipoteichoic acid can bind to cellsurface receptors and are pro-inflammatory, although they are 
much less active than LPS. Their role in the pathogenesis of clinical sepsis remains uncertain 
because there are no convincing clinical data to show that they are present in the circulation at 
concentrations comparable to those used in the experimental setting.  
LPS-induced septic shock 
When LPSs are present in the bloodstream, as a result of a systemic Gram-negative bacterial 
infection, they are immediately captured by LPS-binding protein and then transferred to their 
cognate extracellular receptor complex composed of CD-14, MD-2 and Toll-like receptor 4 
(TLR-4) (Daun JM 2000; Kaisho T 2000). Binding of LPS to the CD-14/MD-2/TLR-4 
receptor complex in target cells, such as monocytes and residential macrophage populations, 
results via TLR-4 associated MYD88 complexes in activation of a diverse set of complex 
signaling cascades including the TRAF6/TAK1/IKK-α/IKK-β-IκB-NF-κB pathway (Akira S 
2001). In macrophages, NF-κB might then upregulate in concert with its coactivator PARP-1 
the expression of specific sets of pro-inflammatory mediators involved in the pathogenesis of 
septic shock: cytokines (TNF-α, MIF, IFN-γ) and interleukins. The massive production and 
release of cytokines by macrophages might then in turn activate in target cells, such as 
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monocyte/macrophage populations and epithelial and endothelial cells, the NF-κB complex in 
concert with other transcription factors, including STAT-1 and AP-1, which results in the 
repeated upregulation of the expression of inflammatory cytokines and chemokines, 
endothelial adhesion molecules including intercellular adhesion molecules (ICAMs), 
endothelial leukocyte cell adhesion molecules (ELAMs, E-selectin), platelet endothelial cell 
adhsion molecule-1 (P-selectin), and vascular cell adhesion molecules. The increased 
expression of these genes in effector cells (epithelial and endothelial cells) results in the 
recruitment and activation of peripheral blood mononuclear cells (PMNs) and macrophages. 
Secretion of pro-inflammatory cytokines by these cells leads to continued stimulation of 
epithelial and endothelial cells that in turn might activate the NF-κB transcription factor. 
Thus, a positive autoregulatory loop might be established that can amplify the inflammatory 
response and increase the duration of chronic inflammation resulting in a persistent activation 
of NF-κB transcription factor characterized by over-expression of pro-inflammatory 
mediators and massive recruitment of PMNs and macrophages. At the same time, TNF-α, IL-
1β and IFN-γ stimulate endothelial cells, PMNs and macrophages to drastically upregulate the 
expression of inducible nitrogen monoxide synthase (iNOS). Cellular iNOS induction in 
effector and target cells results in a massive increase in the concentration of NO. NO can 
diffuse from PMNs and macrophages to endothelial and epithelial cells where it is converted 
into a cytotoxic derivative, peroxynitrite. Rapid single-strand DNA breaks are induced by the 
high concentration of peroxynirtite in effector cells, leading to excessive activation of PARP-
1, depletion of cellular energy and necrotic cell death. Necrosis of endothelial cells then in 
turn might result again in a massive recruitment and activation of PMNs and macrophages as 
a positive feedback loop that finally leads to enhanced systemic inflammation, endothelial 
dysfunction and organ failure. 
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Poly-(ADP-ribose) polymerase (PARP-1) 
Until recently, only one type of poly-(ADP-ribose) polymerase (PARP) was thought to exist: 
the PARP-1. However, the development of mice deficient for the PARP-1 gene has 
completely changed this view. To date, more than 16 new PARP family members can be 
found in the human genome (Shall S 2002).  
 
 
Fig. 2 The structures of the PARP subclasses. 
 
These new PARPs are structurally distinct from the classical 114 kDa PARP-1 enzyme, and 
can be classified together with PARP-1 according to their structures and sizes into several 
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subgroups (Fig. 2). Only limited data are avaliable regarding the physiological roles of these 
nonclassical PARP family members.  
Mammalian PARP-1, a 114 kDa abundant nuclear chromatin associated protein, 
belongs to a large family of enzymes that catalyzes the transfer of ADP-ribose units from 
beta-nicotinamide adenine dinucleotide (NAD+) onto glutamic acid residues of nuclear 
protein acceptors. The existence of a PARP enzyme was first reported nearly 40 years ago. 
PARP-1 in one of the best-characterized examples of this family. The activity of PARP-1 is 
strongly stimulated by the presence of nicks and strand breaks in DNA (Alvarez-Gonzalez R 
1994). These observations have contributed to the idea that PARP mediates stress-induced 
signaling and functions in an NAD+-dependent manner in certain cellular processes (Althaus 
FR 1990; Althaus FR, 1992). Since then, the biological significance of PARP has been 
reported in many cellular processes (D’Amours D 1999; Le Rhun Y 1998; Shall S 2000). 
However, the physiological role of PARP-1 is still under heavy debate. Earlier studies using 
inhibitors of PARP enzymatic activity such as 3-AB and nicotinamide suggested that PARP-1 
plays a crucial role in DNA replication, DNA base excision repair, recombination as well as 
regulation of telomere lenght (Shall S 2000). Other functions proposed for PARP-1 include 
gene expression, chromatin organization, proliferation and differentiation, cellular NAD+ 
metabolism and necrosis. In addition to the PARP-related energetic depletion and suicidal 
cycle, PARP may have other important functions in modulating cell death. Although highly 
controversial, PARP (or its cleavage) may have a role in the process of apoptosis (Kaufman 
SH 1993; Nocholson DW 1995). Several reports demonstrated that peroxynitrite – as well as 
hydrogen peroxide and various other oxygen derived oxidants and free radicals – can cause 
apoptosis in a variety of cell types (Salgo MG 1995; Bonfoco E 1995; Lin KT 1995). It 
appears that sustained exposure or low levels of peroxynitrite cause apoptosis, whereas 
sudden exposure to high concetrations of peroxynitrite induces cell necrosis. However, the 
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peroxynitrite-induced apoptosis, in all cell types studied so far, cannot be attenuated by 
pharmacological inhibitors of PARP or PARP-/- phenotype (Virag L 1998; Leist M 1997; 
Wang ZQ 1997; O’Connor M 1997). PARP-1 also serves as a marker for the onset of 
apoptosis, after which it is cleaved by caspases into DNA-binding and catalytic fragments (Gu 
Y 1995; Tewari M 1995). 
Structure of PARP-1 
PARP-1 is found in all multicellular lower and higher eukaryotes studied so far. The structure 
of the type 1 PARP has been extensively characterized. PARP-1 is a highly conserved 
multifunctional enzyme consisting of three domains: a DNA-binding domain (DBD) 
containing a bipartite nuclear localization signal (NLS) which is interrupted by a caspase 
cleavage site, an automodification domain and a catalytic domain (Fig. 3). Tha catalytic 
domain is the most highly conserved region of the PARP molecule (Murcia G 1994). The N-
terminal DBD of human PARP-1 spans residues 1-373 and has a molecular mass of 
approximately 42 kDa. This domain contains two zinc fingers (FI and FII) and two helix-turn-
helix (HTH) motifs (Gradwohl G 1990; Ikejima M 1990).  
 
 
 
Fig. 3 Schematic representation of the PARP-1 map. Abbreviations: BRCT: BRCA-C-
terminal domain; ZF: zinc finger; HTH: helix-turn-helix domain; LZ: leucine zipper; NLS: 
nuclear localization signal; PRD: PARP regulatory domain. 
 
Studies have shown that these two zinc fingers are the main stuctures responsible for binding 
to double-strand breaks (DSBs) or single-strand breaks (SSBs) and for activation of PARP-1 
enzyme activity. The moderate non-specific association of PARP-1 with non-damaged DNA 
has been proposed to depend most probably on the HTH motifs (Thibodeau J 1993). 
Moreover, the zinc fingers can also act as an interface with various protein partners.  
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The automodification domain of PARP-1 extends from residues 374 to 525 bearing a 
leucine zipper (LZ) motif in the N-terminal part and a BRCA1 carboxyl-terminal (BRCT) 
protein interaction domain in the C-terminal part (Uchida K 1993). Both the LZs and the 
BRCT domain are well known to be involved in protein-protein interactions (Buch SJ 1990; 
Callebaut I 1997). Experimental data suggested that the LZs might be responsible for 
homodimerization of PARP-1 (Kim JW 2000). In addition, the automodification domain 
contains possible auto-poly(ADP-ribosyl)ation sites implicated in the negative regulation of 
interactions between PARP-1 and DNA (Duriez PJ 1997; Mendoza Alvarez H 1999). 
Tissue distribution, expression levels and subcellular localization of PARP-1 
The tissue distribution of PARP-1 and its enzymatic activity have been examined in several 
rat and mouse organs (Ogura T 1999; Menegazzi M 1991). Northern blot analysis and in situ 
hybridization have revealed that PARP-1 gene is constitutively expressed in testis, spleen, 
brain, thymus, intestine, colon and nasal cavities. Very high levels of PARP-1 were found in 
lymphoid organs, especially the thymus, in the germinal centers of the spleen and in the 
Peyer’s patches in the ileum, while only very low levels of PARP-1 expression were found in 
organs such as liver, kidney and heart (Dantzer F 2000). In the central nervous system (CNS), 
PARP-1 is highly expressed in regions with a high neuronal cell density such as hypocampal 
neurons of the regions CA1 and 3, granule cells of the dentate gyrus, Purkinje cells of the 
cerebellar cortex, as well as microglia and astrocytes in several regions (Zucconi G 1992). 
Interestingly, for non-neuronal cell types, a direct correlation could be observed between cell 
proliferation and high expression levels of PARP-1. Several studies have shown that an 
increase in PARP-1 mRNA levels is observed during thymocyte proliferation and upon 
activation of lymphocytes and peripheral blood mononuclear cells (Menegazzi M 1988; 
McNerney R, 1989). Moreover, the PARP-1 mRNA level reaches its peak either in the G1 or 
the S phases (Wesierska-Gadek J, 2000). The tissue-, cell- and cycle-specific expression 
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pattern of PARP-1 suggests strongly not only that PARP-1 is critical to major cellular 
functions but also that its expression is modulated through complex transcriptional regulation. 
Observation of several different tissues and cell lines using conventional fluorescence 
microscopy revealed that PARP-1 is exclusively localized to the nucleus (Cocha I 1989). 
Subsequent studies using either confocal laser scanning microscopy, electron microscopy or 
cell fractionation experiments showed that PARP-1 is not homogeneously distributed in the 
nucleus. PARP-1 was shown to be associated with nuclear matrix regions and localized to 
centromeres during metaphase (Kanai M 2000), while other studies indicated that PARP-1 is 
found preferentially in nucleoli and defined nuclear bodies (Desnoyers S 1996). Interestingly, 
PARP-1 was also shown to be associated with actively transcribing nucleolar regions and 
nuclear bodies. Treatment of cells with RNA synthesis inhibitors caused PARP-1 
immunofluorescence to become evenly distributed throughout the nucleus. The association of 
PARP-1 with actively transcribed regions in the chromatin strongly implies a role for PARP-1 
in transcription. Surprisingly, treatment with DNA synthesis inhibitors did not change the 
distribution of PARP-1 in the nucleus. 
Poly-(ADP-ribosyl)ation responses 
Activation of PARP-1 was proposed to be one of the earliest responses of mammalian cells to 
genotoxic stress (Lindahl T 1995). The enzymatic activity of PARP-1 is strongly stimulated in 
vitro and increased by 10- to 500-fold in the presence of nicks and double strand breaks in 
DNA (D’Amours D 1999). These observations have led to the idea that PARP-1 might act as 
a „molecular nick sensor”, thereby mediating stress-induced signaling in the presence of DNA 
lesions in an NAD+-dependent manner to downstream effectors involved in coordinating the 
cellular response to DNA damage (Althaus FR 1992). The „molecular nick sensor” signaling 
model proposes that PARP-1 recognizes and rapidly binds to DNA strand breaks through its 
zinc fingers and in turn, the catalytic domain of PARP-1 is allosterically activated and starts 
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to synthesize complex branched poly-(ADP-ribose) chains, resulting in automodification of 
PARP-1 itself and probably to extensive modification of histones at sites of DNA strand 
breaks. Modification of chromatin proteins and PARP-1 itself might then subsequently act as 
a strong signal that may rapidly recruit other DNA damage-signaling molecules. 
More than 40 nuclear chromatin-associated proteins have been implicated the function 
as a substrate for PARP-1 and to be modified by poly-(ADP-ribose) chains in vivo. Target 
proteins include topoisomerase I and II, histones, p53 and high-mobility group proteins 
(Kasid UN 1989; Scovassi AI 1993; Wesierska-Gadek J 1996; Boulikas T 1991). In intact 
organisms, PARP-1 itself is the predominant acceptor of poly-(ADP-ribose). Except for 
PARP-1 itself, data about modifications of proteins by PARP-1 in vivo should, however, be 
very cautiously interpreted. Despite intense studies in the last 30 years, neither specific 
glutamic acid residues functioning as poly-(ADP-ribose) acceptor sites nor any specific poly-
(ADP-ribosyl)ation motifs could be identified in vitro. Moreover, only a few of the proposed 
substrates of PARP-1, such as p53, topoisomerase I and histone 1 have been shown to directly 
interact with PARP-1 (Kumari SR 1998; Bauer PI 2001). One has also to stress that the 
physiological consequences of poly-(ADP-ribosyl)ation of the substrates are in most cases 
unknown. Lindahl and collegues (Lindahl T 1995) have even proposed that the minor degree 
of modification of poly-(ADP-ribose) acceptor proteins could be explained as an artificial side 
reaction in vitro. 
PARP-1 -/- mice 
In recent years, several laboratories developed mice deficient for the PARP-1 gene. The three 
different knockout mice were created by interruption of either exon 2, exon 4 or exon 1 of the 
PARP-1 gene in mice (Wang ZQ 1997; Trucco C 1998; Masutani M 1999). Surprisingly, 
PARP-1 -/- mice from all three different laboratories are viable and fertile. Furthermore, they 
did not show any phenotypic abnormalities such as organ failures as one would have clearly 
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expected from the data obtained using inhibitors of PARP enzyme activity and taking into 
account that knockouts of genes like XRCC1, DNA polymerase-β or APE, which play a 
crucial role in the BER pathway are lethal (Xanthoudakis S 1996; Tebbs RS 1999; Sugo N 
2000). Indeed, carefully designed studies with PARP-1 -/- cells clearly demonstrated that 
PARP-1 is dispensable and not essential for replication, repair of DNA damage or apoptosis 
in vitro or in vivo (Ha HC 1999; Vodenicharov MD 2000). Interestingly, recent studies using 
PARP-1 -/- mice showed that they were protected against lipopolysaccharide (LPS)-induced 
septic shock, collagen-induced arthritis, streptozotocin-induced diabetes, hemorrhagic shock 
and neuronal damage induced by transient middle cerebral artery occlusion (MCAO) and 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), indicating that PARP-1 plays a crucial 
role in inflammatory and neurodegenerative disorders and is involved in the pathogenesis of 
these events (Szabo C 1997; Pieper AA 1999; Oliver FJ 1999; Mandir AS 1999; Eliasson MJ 
1997; Liaudet L 2000). 
Pharmacological inhibition of PARP-1 in mice 
Current strategies aimed at limiting free radical-mediated and oxidant-mediated cell/organ 
injury include agents that catalyze superoxide or peroxynitrite, or inhibit the induction or 
activity of the inducible NO synthase. Less attention has been directed to strategies that 
interfere with intracellular cytotoxic pathways initiated by nitrogen- or oxygen-derived free 
radicals or their toxic derivatives. Direct and indirect experimental evidence presented in 
several papers supports the view that peroxynitrite-induced DNA strand breakage and PARP 
activation importantly contribute to the pathophysiology of various forms of inflammation.  
Pharmacological inhibition of PARP, either with 3-AB (Szabo A, 1998, Shock) or with the 
potent, novel PARP inhibitors 5-iodo-6-amino-1,2-benzopyrone (Szabo C 1997; Bauer PI 
1995) improves survival rate in mice challenged with high dose endotoxin. Also, several 
recent studies compared the survival times of wild-type and PARP-deficient mice in response 
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to high dose endotoxin, and compared the degree and nature of liver damage in the two 
experimental groups. In one study, all PARP-deficient animals survived high dose (20 mg/kg) 
LPS-mediated shock, which killed 60 % of wild-type animals (Kuhnle S 1999). Similar 
results were obtained by another independent group, led by DeMurcia (Oliver FJ 1999). 
Szabo C and his group reported that 100% mortality in the wild-type group and less than 50 % 
mortality in the PARP-deficient animals was observed at 48 h after intraperitoneal injection of 
high dose (120 mg/kg) E. coli endotoxin. Moreover, LPS-induced necrotic liver damage was 
significantly reduced in the PARP-deficient mice (Kuhnle S 1999). In contrast, when 
apoptotic liver damage was induced via injection of low concentrations of LPS (30 mg/kg) 
into D-galactosamine-sensitized mice, or via activation of hepatic cell death receptors, PARP-
deficient animals were not protected. Thus, PARP activation is involved in systemic LPS 
toxicity, while it plays a minor role in apoptotic liver damage mediated by tumor necrosis 
factor or CD95. 
All of the above-described experiments utilized bacterial components, such as 
endotoxin or hemorrhage and resusciation. It is generally believed that sepsis induced by live 
bacteria is more appropriate in mimicking the human septic condition. In a preliminary study, 
Szabo et al (in: PARP as a therapeutic target) compared the survival rates of wild-type and 
PARP-deficient mice to cecal ligation and puncture (CLP), a commonly used model of 
polymicrobial sepsis. Their found that CLP-induced death was delayed in the PARP-deficient 
mice when compared with wild type animals. The beneficial effects of PARP inhibition in 
bacterial sepsis were also confirmed in a model of sepsis induced by live E. coli sponge 
implantation in pigs. Pharmacological inhibition of PARP provides marked hemodynamic 
improvements and massive survival benefit (Marton A 2001). 
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Fig. 4 Overview of the connection between septic shock, PARP activation and 
inflammatory mechanisms. In sepsis LPS induces the overproduction of pro-inflammatory 
cytokines and chemokines. The PMN-cell activation and the induction of iNOS leads to free 
radical and oxidant generation. These agents cause ssDNA breaks and activation of PARP. 
PARP activation leads to energy depletion, cellular metabolic supression, mitochondrial 
dysfunction and cell necrosis. After all these processes cause failures of several systems and 
subsequent death. PARP inhibitors can interfere in a relatively early stage of this process. 
 
Based on these observations, one can conclude that, in response to pharmacological inhibition 
or genetic deletion of PARP, the improved hemodynamic status in shock and sepsis is due to 
improved vascular function and, possibly, the improved cellular energetic status in some 
organs. These improvements, in turn, result in an overall survival benefit in this condition 
(Fig. 4). 
Moreover, in the past few years an increasing number of reports have appeared about 
the importance of the PI3-kinase/Akt and MAPK pathways in LPS-induced inflammatory 
mechanisms (Bozinovski S 2002; Guha M 2002; Ozes ON 1999). Recent evidence suggests 
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that activation of PI3-kinase, a ubiquitous lipid-modifying enzyme, may modulate positively 
acting signaling pathways and inhibition of LPS-induced MAPKs activation may play crucial 
role in the attenuation of endotoxin-induced inflammatory responses due to the modulation of 
transcription factors. 
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Objectives. 
 
Studies utilising the traditional PARP-1 inhibitor, 3-AB, suggested that PARP-1 
activity has no (Baechtold F 2001) or partial (Albertini M 2000) role in the mechanisms of 
septic shock. However, 3-AB is considered a poor inhibitor of PARP-1 with short cellular 
residence time and it has pronounced toxicity in vivo. A separate group in our laboratory 
demonstrated (Kovacs K 2002) that novel PARP-1 inhibitors protected Langendorff-perfused 
hearts against ischemia-reperfusion-induced damages by modulating signal transduction 
pathways and transcription factors.  
Therefore, it seemed plausible to study whether these processes were involved in the 
effects of potent PARP-1 inhibitors - PJ34 and 4-HQN - on LPS-induced septic shock. 
PJ34: Phenanthridinone was described as a fairly potent inhibitor of PARP-1. 
However, the compound is not water soluble, and it has not been tested in models of shock 
and reperfusion injury in vivo. PJ34 (N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-
dimethylamino)acetamide hydrochloride, C17H18ClN3O2· 0.5H2O) (Fig. 5) is a selected water 
soluble member of the PJ series of phenanthridinone-based PARP-1 inhibitors (Jagtap P 
2002). 
 
 
 
 
 
 
 
Fig. 5 Basic structure of PJ34. 
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4-HQN: Several different quinazoline-derivatives were reported as potent PARP-1 
inhibitors (Banasik M 1992) and 4-HQN (Fig. 6) is one of them. It is structurally unrelated to 
PJ34 and it was reported to protect hearts from ischemia-reperfusion-induced damages 
(Halmosi R 2001). 
 
 
 
 
 
 
Fig. 6 Basic structure of 4-hydroxyquinazoline. 
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Materials and Methods. 
 
Animals. BALB/c mice were purchased from Charles River Hungary Breeding LTD. The 
animals were kept under standardized conditions; tap water and mouse chow were provided 
ad libitum during the whole experimental procedure. Animals were treated in compliance with 
approved institutional animal care guidelines. 
 
Materials. LPS from Escherichia coli 0127:B8 was purchased from Sigma/Aldrich; N-(6-oxo-
5,6-dihydro-phenanthridin-2-yl)-N,N-dimethylacetamide HCl (PJ34) was synthesized as 
previously described and it was a kind gift of Szabo C., 4-hydroxyquinazoline (4-HQN) was 
purchased from Sigma/Aldrich. Primary antibodies, anti-phospho-p44/42 MAP kinase 
(Thr202/Tyr204), anti-phospho-Akt (Ser473, Thr308), anti-phospho-GSK-3β (Ser9), anti-
phospho-SAPK/JNK (Thr183/Tyr185), anti-phospho-p90RSK (Thr359/Ser363) were from 
Cell Signaling Technology; anti-phospho-p38 (Thr180/Tyr182) was from Sigma; anti-HMG-1 
was from Becton Dickinson and anti-COX-2 was from Santa Cruz Biotechnology. 
 
Sepsis model. To induce murine endotoxic shock, BALB/c mice were injected i.p. with LPS 
at a dose of 20 mg/kg body weight in a volume of 250 µl. PJ34 (10 mg/kg) was administered 
i.p. in a volume of 250 µl three times on the day preceding the LPS challenge (pre-treatment), 
or as a single dose 1 or 6 hours after the LPS injection. With 4-HQN (100 mg/kg) treatment, 
we used the same protocol. Control mice received the same volume of sterile saline solution 
instead of the PARP-1 inhibitors. The mice were monitored for clinical signs of endotoxemia 
and lethality every hour for 48 hrs, after which time they were monitored three times a day for 
1 week. No late deaths were observed in any of the experimental groups. Each experimental 
group consisted of 10 mice. Data represent mean of 3 independent experiments. 
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4-HQN was reported as a potential PARP-1 inhibitor (Banasik M 1992) with an IC  
9,5 microM. We have measured the inhibitory effect of 4-HQN on PARP-1, and our results 
were in agreement with the above mentioned data (IC 8-12 microM). In accordance with the 
notion that an animal model requires higher dose than an in vitro system we selected 100 
mg/kg dose, which had a significant protective effect in the survival studies. In a previous 
study 
50 
50 
(Halmosi R 2001), we have established that this dose of 4-HQN effectively inhibited 
PARP-1 activity in Langerdorff-perfused hearts, because it prevented the ischemia-induced 
ADP-ribosylation of proteins. Since this substance has a high potency on PARP-1 and no 
effects of it on enzymes other than PARP have been documented, it seemed likely that our 
observations could assigned to its PARP inhibitory effect.
 
Western blot analysis. For Western blot analysis, groups of 4 BALB/c mice were pre-treated 
or not with 10 mg/kg PJ34 or 100 mg/kg 4-HQN three times a day one day prior to the LPS-
challenge (20 mg/kg). Liver, heart, lung, spleen and small intestine were removed from the 
animals 16 hours after the LPS treatment, were frozen in liquid N2 and were processed exactly 
as described previously (Szabados E 2000). Protein load was 35 µg/lane. We applied the 
primary antibodies: anti-COX-2, anti-phospho-Akt (Ser473), anti-phospho-Akt (Thr308), 
anti-phospho-p44/42 MAP kinase (Thr202/Tyr204), anti-phospho-GSK-3β (Ser9), anti-
phospho-SAPK/JNK (Thr183/Tyr185), anti-phospho-p90RSK (Thr359/Ser363), anti-
phospho-p38 (Thr180/Tyr182) and anti-HMG-1 protein at 4°C overnight at a dilution of 1:500 
(anti COX-2) and 1:1000 (all the rest). The secondary antibodies were horseradish 
peroxidase-conjugated rabbit IgG. Peroxidase labeling was visualized with the SuperSignal 
West Pico Chemiluminescent Substrate (Pierce Biotechnology). 
Quantification of band intensities (E540) of the blots was performed by a Beckman 
DU-62 spectrophotometer equipped with a densitometry attachment (Beckman Instruments) 
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and ImageJ software. Data representing 3 independent experiments are expressed as % of the 
untreated control, mean ± S.E.M. 
 
TNF-α determination. Mice were treated exactly as for Western blot analysis. Serum TNF-α 
concentrations were determined with the Quantikine M TNF-α immunoassay kit (R&D 
Systems). Blood samples were taken 1.5 hours after LPS administration and were allowed to 
clot for 0.5 hour at room temperature before centrifuging for 20 minutes at 2000 × g. The 
serum was removed and assayed immediately. To calculate the results, we created a standard 
curve by reducing the data using computer software to generate a four parameter logistic (4-
PL) curve-fit. The mouse TNF-α standard dilution series was prepared in accordance with the 
protocol of the manufacturer. Data represent mean ± S.E.M. of 12 independent values (three 
independent experiments with 4 mice in each group.). 
 
Determination of NF-κB and AP-1/c-Fos activation. Mice were treated exactly as for Western 
blot analysis. For nucleus isolation, liver, spleen and lung were removed 1.5 hours after the 
LPS-treatment and were homogenised immediately according to the procedure described 
previously (Edmead C 1999). Protein concentrations in nuclear extracts were determined 
using a bicinchoninic acid assay with bovine serum albumin (BSA) as standard (Sigma). To 
monitor NF-κB   and AP-1 c-Fos activation in tissues, we used Trans-AMTM Transcription 
Factor Assay Kits (Active Motif). The kits consists of 96-well plates into which 
oligonucleotides containing the NF-κB  and AP-1 c-Fos consensus sites (5’-GGGACTTTCC-
3’; 5’-TGAGTCA-3’ respectively) are bound. The active forms of the above mentioned 
transcription factors in the nuclear extract specifically bind to these consensus sites and are 
recognised by primary antibodies. A horseradish peroxidase-conjugated secondary antibody 
provides the basis for the colorimetric quantification. Results were expressed as percentages 
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of the positive controls (TNF-α stimulated HeLa whole cell extract and WI-38 nuclear cell 
extract respectively) provided by the manufacturer and represent mean ± S.E.M. of 12 
independent values (Three independent experiments with 4 mice in each group.). 
 
Histopathological analysis. Mice were treated exactly as for Western blot analysis. For 
histopathological analysis, liver, kidney, heart, spleen and small intestine were removed from 
the animals 16 hrs after LPS injection, fixed in 4% formaldehyde, blocked, cut into sections 
of 10 µm in thickness, and stained with hematoxylin and eosin. Scoring of the LPS-induced 
histopathological changes was performed by an expert pathologist who was blind to the 
experiment. 
 
MRI analysis. Mice were treated exactly as for Western blot analysis. Six hours after LPS 
treatment, the animals were anaesthetised with urethane (1.7 g/kg administered i.p.) and were 
placed into an epoxy resin animal holder tube. 
MRI measurements were performed on a Varian UNITYINOVA 400 spectrometer 
(Varian, Inc.) with a 89 mm vertical bore magnet of 9.4 T (Oxford Instruments Ltd.) using a 
35 mm inner diameter hollow micro-imaging probe with a built-in self-shielded gradient 
system up to 400 mT/m (Doty Scientific, Inc.). After tuning, shimming (1H linewidth ≈ 150 
Hz) and RF calibration, the slice of interest was selected using a T1-weighted multislice spin-
echo sequence (4.0 ms sinc pulses, TR = 1000 ms, TE = 12 ms, slice thickness = 1 mm, FOV 
= 30 mm × 30 mm, acquisition matrix 128 × 128). T2-weighted images were recorded using a 
multislice spin-echo sequence (parameters were like at T1-weighting, except TR = 3000 ms 
and TE = 50 ms). One average was taken and images were reconstructed as 256 × 256 
matrices. The intensities of the images were standardised to the signal of a 1 mm inner 
diameter tube filled with water : glycerol = 9 : 1, which was placed near the animal during the 
measurements. Mean signal intensities were measured and expressed as a percentage of the 
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signal intensity of the internal standard in characteristic regions delineated as freehand areas 
by experts who were blind to the experiment. Due to individual differences among the 
animals, with special respect to uncertainity of the their posture and position (i.e. orientation 
of their internal organs) within the magnet of the NMR instrument, this scoring should be 
considered as semiquantitative. Experiments were repeated 3 times. 
 Inflammation affected regions appear in T2-weighted MRI with increased signal 
intensity, due to cellular invasion and edema, as reported recently for paraspinal or epidural 
inflammation and soft tissue inflammation (Ledermann HP 2002). Agreement between MRI 
data and histopathology was found to be satisfactory for acute local infection in mouse muscle 
(Ruiz-Cabello J 2002). 
 
Statistical analysis. When pertinent, data were presented as means ± S.E.M. For multiple 
comparisons of groups, ANOVA was used. Statistical difference between groups was 
established by paired or unpaired Student’s t-test, with Bonferroni’s correction. 
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Results. 
 
Survival studies 
 
Mice treated with a single dose of LPS (20 mg/kg) died within 65 hours. When the mice were 
pre-treated three times a day, one day before the LPS challenge by PJ34 (10 mg/kg) or by 4-
HQN (100 mg/kg), 100 % or 80 % of the animals in the group survived, respectively. Even 
when groups of mice received only a single shot of PJ34 (10 mg/kg) 1 or 6 hours after the 
LPS challenge, the PARP-1 inhibitor significantly protected the animals against LPS-induced 
death, with 86 and 43 % surviving mice, respectively (Fig. 7).  
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Fig. 7 Effect of PJ34 on the LPS-induced mortality in mice. PJ34 (10 mg/kg, i.p.) was 
injected three times a day one day prior the LPS (20 mg/kg, i.p.) treatment (pre-treatment with 
PARP-inhibitor) or was injected in a single dose (10 mg/kg, i.p.) 1 or 6 hours after LPS (post-
treatment with PARP-inhibitor). 
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A single shot of 4-HQN (100 mg/kg) 1 hour after the LPS challenge, with a less 
efficiency in compared with PJ34, but significantly protected the animals against LPS-
induced death, with 30 % surviving mice. In contrast to PJ34, when 4-HQN were 
administered 6 hours after LPS challenge in a single shot (100 mg/kg) it had no protective 
effect (Fig. 8). PJ34 or 4-HQN treatment itself did not induce death or any obvious damage 
(data not shown). 
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Fig. 8 Effect of 4-HQN on the LPS-induced mortality in mice. 4-HQN (100 mg/kg, i.p.) 
was injected three times a day one day prior the LPS (20 mg/kg, i.p.) treatment (pre-treatment 
with PARP-1 inhibitor) or was injected in a single dose (100 mg/kg, i.p.) 1 or 6 hours after 
LPS (post-treatment with PARP-1 inhibitor). 
 
MRI-analysis 
 
Untreated, PARP-inhibitor pre-treated, LPS-treated and LPS + PARP-inhibitor pre-treated 
mice underwent MRI-analysis. T2-weighted transversal spin-echo images were taken from the 
thoracic and lower abdominal regions. Signal intensities of T2 images were proportional to the 
inflammatory response.  
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Fig. 9-10 Effect of PARP inhibitor treatment on T2-weighted MR images of the thoracic 
(upper row) and the lower abdominal (lower row) region in mice. Typical T2-weighted 
images of untreated (left column), LPS (20 mg/kg, i.p.) treated (middle column), LPS + PJ34 
(20 mg/kg, i.p. LPS and 3 × 10 mg/kg PJ34 i.p.) treated (right column) (Fig. 7) and untreated 
(left column), LPS (20 mg/kg, i.p.) treated (middle column) and LPS + 4-HQN (20 mg/kg, i.p. 
LPS and 3 × 100 mg/kg 4-HQN i.p.) treated (right column) mice (n = 4 in each group) are 
shown. The thoracic region of LPS treated mice showed a marked increase of intensity 
(inflammation) especially in the peripheral (arrows) and in the dorsal subcutaneous 
(arrowhead) regions. The lower abdominal region of LPS treated mice showed marked 
increase of intensity (inflammation) especially in the lateral subcutaneous regions (arrows) 
and the inter-intestinal cavities as well as around the kidneys (arrowheads). In animals treated 
with LPS and PJ34 or LPS and 4-HQN, the T2-weighted intensities were markedly lower, so 
the inflammatory response was significantly smaller. T2-weighted images of animals treated 
with PJ34 or 4-HQN alone were basically identical to images of untreated mice. 
 
Table 1. Normalized pixel intensities of MRI T2-weighted images 
 
 
 Untreated  LPS-treated LPS+4HQN  LPS+PJ34 
   treated treated 
 
 
thorax whole slice 54.4 ± 2.4 95.1 ± 5.7* 68.2 ± 2.6 # 62.7 ± 4.4# 
 
thorax muscles and  
subcutaneous region 87.3 ± 2.4 124.7 ± 5.5* 106.2 ± 4.6 # 97 ± 8.1#
 
abdomen whole slice 42.8 ± 1.3 145.5 ± 5.0* 78.5 ± 2.6 # 80.1 ± 3.4#
 
abdomen  
gastro-intestinal tract 34.7 ± 1.6 162.0 ± 6.4* 75.6 ± 5.3 # 84.2 ± 6.9#
 
 
Mean pixel intensities (± SEM) of T2-weighted images were expressed as the percentage of 
the mean intensity of the internal standard (water : glycerol = 9 : 1). 
 ∗ P < 0.01 vs. untreated; # P < 0.05 vs. LPS-treated. 
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Representative images selected from 12 images for each group are presented in Fig. 9-10 and 
normalized mean pixel intensities for all the images were summarized in Table I. 
T2-weighted images of the thoracic regions showed considerably increased intensities 
in the dorsal subcutaneous region, moderately increased intensities in the intramuscular 
regions and no observable difference in and inside the pleura of the LPS-treated mice. In the 
abdominal regions, characteristic increases were observed around the kidneys, in the inter-
intestinal cavities and in the gastro-intestinal tract. On the other hand, no signal increase could 
be observed inside the kidneys and in skeletal muscle, neither in the paravertebral nor in the 
femoral muscles. All increases in signal intensities were significantly attenuated in mice pre-
treated with PJ34 or 4-HQN, indicating that the PARP-1 inhibitors reversed the LPS-induced 
morphological changes. Mice pre-treated with PJ34 or 4-HQN alone were identical to the 
untreated control (data not shown). 
 
Effect of PARP inhibitors on LPS-induced pathological changes.  
 
Within 2 hours after the LPS-injection, we observed hypomotility, hypothermia, tremor, 
diarrhea and a characteristic crouching gait among the treated mice. Despite the serious 
symptoms and the rapid death, we found surprisingly few pathological changes 16 hours after 
the LPS-treatment. There were no notable pathological changes in the heart, spleen and 
kidney. In the small intestine, LPS induced a considerable atrophy of villi (Fig. 11b) that was 
prevented by PJ34 pre-treatment (Fig. 11c) but not by 4-HQN (data not shown). In the liver, 
we observed focal necrotic and necrobiotic damages (Fig. 11e), sporadic basophilic apoptotic 
nuclei (Fig. 11f) and blood vessels obstructed with cell-rich material either attaching to the 
wall of the blood vessels or obstructing the whole lumen (Fig. 11g). PJ34 pre-treatment 
significantly protected the tissue against the necrotic and apoptotic damage, as well as against 
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the obstruction of blood vessels caused by LPS (Fig. 11h). 4-HQN had no significantly 
protective effect on the above mentioned pathological changes (data not shown). Mice treated 
with PJ34 or 4-HQN alone did not show any pathological changes. 
 
Fig. 11 Histology of the liver and the small intestine. Mice were treated with LPS (20 
mg/kg, i.p.) either with or without of PJ34 (3 × 10 mg/kg, i.p.) pre-treatment. Tissues were 
collected 16 hours after LPS injection. Sections were stained with hematoxylin-eosin (HE). a: 
tissue of normal control gut; b: LPS-induced atrophy of villi; c: atrophy of villi prevented by 
PJ34 pre-treatment; d: tissue of normal control liver; LPS-induced necrotic (e), apoptotic 
damage (f) and obstructed blood vessels (g); h: PJ34 pre-treatment largely prevented the 
effects of LPS in the liver. Original magnification: 100 × (a, b, c); 250 × (d, g, h); 300 × (e, f). 
Tissues from animals treated with PJ34 alone were identical to control. 
 
Effect of PARP inhibitors on LPS-induced TNF-α production. 
 
LPS-treatment resulted in a rapid increase in serum TNF-α concentration which reached 2960 
± 112 pg/ml after 90 minutes (Fig. 12). In the PJ34 and 4-HQN treated mice, LPS challenge 
resulted in a significantly lower TNF-α concentrations (1150 ± 122 pg/ml; 1500 ± 135 pg/ml 
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respectively). PJ34 and 4-HQN alone did not exert any significant effect on serum TNF-α 
levels (Fig. 12). 
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Utilising phosphorylation-specific antibody against phospho-Akt (Ser473) region, we were 
able to demonstrate activation of Akt under our experimental conditions. We did not find Akt 
activation in tissues of untreated animals or in animals treated with LPS alone. In every tissue 
we studied there was a marked increase in the phosphorylation and thereby the activation of 
Akt of 4-HQN and 4-HQN + LPS treated mice (Fig. 13). This activation reached 2880 ± 144 
% in spleen, 835 ± 54 % in liver and 957 ± 103 % in lung in animals treated with 4-HQN 
+LPS and 416 ± 57 %, 554 ± 19 % and 1158 ± 97 % in animals treated with 4-HQN alone, 
respectively. Using an antibody against phospho Akt Thr308 region we did not find Akt 
activation neither with LPS nor with 4-HQN treatment (data not shown). Under our 
experimental condition we could not detect phospho-GSK-3β (Ser9) synthesis even though 
our assay system was able to detect GSK-3β phosphorylation in other systems (data not 
shown). 
 Extracellular signal-regulated kinase phosphorylation and activation was determined 
by Western blotting using an anti-phospho-p44/42 MAP kinase (Thr202/Tyr204) antibody. LPS-
treatment resulted a marked increase in activation of ERK ½ in the spleen (4360 ± 270%), 
liver (5025 ± 345%) and in the lung (4575 ± 298 %). Pre-treatment with 4-HQN significantly 
attenuated this activation in all three tissues (2022 ± 125 %, 1358 ± 97 % and 2174 ± 203 % 
respectively). 4-HQN treatment itself did not have any effect on the activation of phospho-
ERK ½ in the tissues we studied (Fig. 14). 
 p90RSK is a downstream target of p44/42 MAP kinase in the ERK pathway. 
Phosphorylation of p90RSK was determined using an anti-phospho p90RSK antibody. In the 
lung of LPS-treated mice we found a marked activation of p90RSK (5964 ± 420 %), which 
was attenuated by 4-HQN pre-treatment (4550 ± 121 %) (Fig. 15). However, in spleen and in 
liver LPS did not induce the activation of p90RSK and 4-HQN had no additional effect (data 
not shown). 
 32
  
spleen 
 
 
lung 
 
 
liver 
 
1 2 3 4  
Fig. 13 Activation of Akt by 4-HQN pre-treatment. The effect of 4-HQN pre-treatment on 
Akt activation was evaluated by Western blot analysis in the extracts of various tissues. 
Lane1: control (injected with physiological saline); Lane 2: LPS (20 mg/kg, i.p.); Lane 3: LPS 
+ 4-HQN: pre-treated with 4-HQN (3 × 100 mg/kg, i.p.) and injected with LPS (20 mg/kg, 
i.p.); Lane 4: 4-HQN (injected with 100 mg/kg 4-HQN alone). 
 
 
 
 
 
 
 
 
 
Fig. 14 Inhibition of ERK 1/2 MAPK by 4-HQN pre-treatment. The effect of 4-HQN pre-
treatment on ERK 1/2 inhibition was evaluated by Western blot analysis in the extracts of 
various tissues. Lane1: control (injected with physiological saline); Lane 2: LPS (20 mg/kg, 
i.p.); Lane 3: LPS + 4-HQN: pre-treated with 4-HQN (3 × 100 mg/kg, i.p.) and injected with 
LPS (20 mg/kg, i.p.); Lane 4: 4-HQN (injected with 100  
liver 
lung 
spleen 
4 3 2 1 
mg/kg 4-HQN alone).
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Fig. 15 Effect of 4-HQN on phosphorylation of p90RSK in lung. Lane1: control (injected 
with physiological saline); Lane 2: LPS (20 mg/kg, i.p.); Lane 3: LPS + 4-HQN: pre-treated 
with 4-HQN (3 × 100 mg/kg, i.p.) and injected with LPS (20 mg/kg, i.p.); Lane 4: 4-HQN 
(injected with 100 mg/kg 4-HQN alone). 
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Fig. 16 Inhibition of p38 MAPK by 4-HQN pre-treatment in lung. Lane1: control 
(injected with physiological saline); Lane 2: LPS (20 mg/kg, i.p.); Lane 3: LPS + 4-HQN: 
pre-treated with 4-HQN (3 × 100 mg/kg, i.p.) and injected with LPS (20 mg/kg, i.p.); Lane 4: 
4-HQN (injected with 100 mg/kg 4-HQN alone). 
 
Phosphorylation of MAPK p38 was determined using an anti-phospho p38 antibody. 
As shown in Fig. 16, LPS-stimulated p38 activation in the lung (368 ± 42 %) was completely 
abolished by 4-HQN pre-treatment. However, in spleen and in liver LPS did not induce the 
activation of p38 and 4-HQN had no additional effect (data not shown). 
Under our experimental condition we could not detect phospho-JNK (Thr183/Tyr185) 
synthesis even though our assay system was able to detect JNK phosphorylation in other 
systems (data not shown). 
COX-2 and HMG-1 expression was determined by Western blotting from lung, heart, 
liver and small intestine of untreated mice, mice treated with LPS or PJ34, and from 
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PJ34+LPS-treated mice. Regardless of the treatment, we did not find significant changes in 
COX-2 and HMG-1 expression in these tissues (Fig. 17).  
Utilising phosphorylation-specific antibodies against phospho-Akt (Ser473 and Thr308) 
regions, we were able to demonstrate activation of Akt under our experimental conditions. 
There was an activation of the Akt-system close to the detection limit in all tissues of 
untreated animals (Ser473 liver: 4040 ± 354; small intestine: 4601 ± 478; Thr308 liver: 2126 ± 
155; small intestine: 1945 ± 177) (Fig. 17) or in animals treated with PJ34 alone (data not 
shown).  
Fig. 17 Western blot analysis of COX-2, phospho-Akt Thr308, phospho-Akt Ser473 and 
HMG-1 expression in the liver and in the small intestine. Lanes; 1: control liver; 2: control 
small intestine; 3: liver of LPS treated mice; 4: small intestine of LPS treated mice; 5: liver of 
LPS + PJ34 treated mice; 6: small intestine of LPS + PJ34 treated mice. Control: injected with 
physiological saline; PJ34: injected with PJ34 (3 × 10 mg/kg, i.p.); LPS: injected with LPS 
(20 mg/kg, i.p.); LPS+PJ34: pre-treated with PJ34 (3 × 10 mg/kg, i.p.) and injected with LPS 
(20 mg/kg, i.p.). 
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Regardless of the treatment, this activation did not increase in lung and heart (data not 
shown). LPS-treatment resulted in a slight, but not significant Akt activation (Fig. 17) in liver 
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(Ser473 4865 ± 455; Thr308 2479 ± 255) and small intestine (Ser473 4996 ± 604; Thr308 2416 ± 
306). However, there was a marked increase in the phosphorylation and thereby the activation 
of Akt in the liver (Ser473 14104 ± 587; Thr308 10942 ± 455) and small intestine (Ser473 14186 
± 688; Thr308 13035 ± 870) of PJ34 + LPS treated mice. 
 
Effect of PARP inhibitors on LPS-induced transcription factor activation. 
 
Ninety minutes after LPS-treatment, NF-κB activation was assessed in lung and liver.  
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LPS-treatment caused a significant increase in NF-κB activation in both tissues. NF-
κB activation in the lung was attenuated slightly but statistically not significantly by PJ34 pre-
treatment. In contrast to the lung, NF-κB activation in the liver was prevented by PJ34 pre-
treatment. PJ34 treatment itself did not have any effect on NF-κB activation in the tissues we 
studied (Fig. 18).  
However, 4-HQN pre-treatment decreased the LPS-induced NF-κB activation in the 
lung and in the liver also. 4-HQN pre-treatment itself did not have any effect on NF-κB 
activation in the these tissues (Fig. 19). 
Lung
0
500
1000
1500
2000
control LPS LPS+4-HQN 4-HQN
ab
so
rb
an
ce
 4
50
nm
 
**
Liver
0
500
1000
1500
2000
control LPS LPS+4-HQN 4-HQN
ab
so
rb
an
ce
 4
50
nm
 
** 
Fig. 19 Effect of 4-HQN on NF-κB activation in the lung and liver in mice at 1.5 hours 
after LPS injection, with and without 4-HQN pre-treatment. Results are expressed as 
percentages of the positive control provided by the manufacturer. Control: injected with 
physiological saline; 4-HQN: injected with 4-HQN (3 × 100 mg/kg, i.p.); LPS: injected with 
LPS (20 mg/kg, i.p.); LPS + 4-HQN: pre-treated with 4-HQN (3 × 100 mg/kg, i.p.) and 
injected with LPS (20 mg/kg, i.p.). Data is expressed as mean ± SEM of 12 independent 
values. n.s. = non significant, ∗∗ P < 0.01 vs. LPS. 
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 the effect of 4-HQN pre-treatment 
 and lung. LPS-treatment caused a 
significant increase in c-Fos activation in all three tissues. 4-HQN pre-treatment significantly 
inhibited this activation in the tissues we studied (Fig. 20). 4-HQN treatment itself did not 
have any effect on c-Fos activation in the studied tissues. 
 
Discussion. 
 
Despite the importance of LPS as a trigger of innate host defenses and inflammation, very 
little is known of the pathomechanism and actual transduction pathways activated by this 
endotoxin. Our study demonstrates that PJ34 and 4-hydroxyquinazoline, potent PARP-1 
inhibitors, had protective effect in LPS-induced murine septic shock model, in part by 
activating the PI3 kinase/Akt cytoprotective pathway and inhibiting the ERK 1/2 and p38 
MAPK pathways.  
Within 2 hours after LPS-injection, the mice exhibited signs of hypomotility, 
hypothermia, tremor, diarrhea and a characteristic crouching gait. Despite the serious 
symptoms and the rapid death (within 65 hours), we found surprisingly few pathological 
changes 16 hours after the LPS treatment. We detected LPS-induced pathological changes 
only in the liver and small intestine among the tissues studied. In a recent paper, Pacher et al. 
(2002) describe severe depression of the systolic and diastolic contractile function, 
tachycardia, and a reduction in mean arterial blood pressure in both rats and mice as a 
consequence of LPS challenge. They used a much higher dose of LPS than us (55 vs. 20 
mg/kg, same serotype), but did not perform a pathological study, so we are unable to 
determine if the absence of pathological changes in hearts in our study was due to the lower 
LPS dose. On the other hand, obstructed blood vessels in the liver as well as the hypothermia 
of the LPS-treated mice reflected disturbed cardiac functions under our experimental 
conditions too. Necrotic and necrobiotic damage and the appearance of apoptotic cells 
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observed by us in the liver of LPS treated mice indicated disturbed microcirculation and the 
resulting tissue hypoxia (Pacher P 2002). It is in accordance with the previous observation 
that LPS treatment decreases liver oxygen uptake from blood vessels (Collins AS 1990). 
The other tissue with observable LPS-induced pathological changes was the small 
intestine. Atrophy of villi may reflect the diarrhea observed in the LPS-treated animals and is 
in agreement with the results of Abreu et al. (2001) who found a Fas-mediated apoptosis in 
intestinal epithelial cells that was sensitized by inhibitors of phosphatidylinositol 3-kinase and 
opposed by expressing constitutively active Akt. 
The in vivo response to endotoxin-induced septic shock was detected by MRI technics. 
Six hours after LPS administration, we observed markedly increased intensities of T2-
weighted MRI images of the thoracic and lower abdominal region of the animals. This 
method provides a real time insight into inflammatory processes in living animals even in 
cases where no histologic alteration can be detected. Among all the observed LPS-induced 
inflammatory responses, we found the most characteristic and most pronounced increases in 
the gastro-intestinal and in the thoracic tract (Fig. 2) similar to that found in a porcine 
endotoxic shock model (Oldner A 1999). The importance of these tracts in the mediation of 
sepsis and multiple-system organ failure is well documented (Boulares AH 2003; Standiford 
TJ 1995). Pre-treatment of the animals with potent PARP-1 inhibitors, PJ34 and 4-HQN, 
diminished the thoracic and abdominal inflammatory responses as revealed by T2 imaging 
(Fig. 2) and abolished the above mentioned pathological changes. 
These data together with the finding that PARP-1 knock out mice were resistant to 
septic shock (Oliver FJ 1999; Soriano FG 2002) indicate that PARP activity is involved in the 
mechanism of septic shock. This view was previously challenged (Baechtold F 2001; 
Albertini M 2000). However, these studies utilised 3-AB, an inhibitor with low potency and 
considerable toxicity in vivo. One of these studies has utilised a cecal ligature and puncture 
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(CLP) model that may represent a more clinically relevant animal model of sepsis than the 
LPS challenge used by us. However, they have found higher 24-hour mortality (5/15) in their 
CLP + 3AB group than in their CLP only group (1/15). This difference, although CLP + 3AB 
not statistically significant, may reflect the in vivo toxicity of 3-AB. It is also noteworthy that 
since in the vehicle treated CLP group only a very low mortality was detected, the design of 
this above referenced particular study (Baechtold F 2001) would not have permitted a 
demonstration of significant improvements in survival rate by PARP inhibitors or by any 
other pharmacological agent. 
In order to determine whether PARP-1 inhibition interferes with early or late 
mediators of LPS-induced septic shock, we performed survival studies in which we 
administered the PARP-1 inhibitors 1 or 6 hours after the LPS challenge. With a decreasing 
efficacy (compare mortality of 4/30 for +1 hour and 17/30 for +6 hours), PJ34 protected the 
mice against LPS-induced death even when added after the induction of the septic shock. 
These findings suggest that PJ34 may interfere with both the early and late mediators of the 
effect of LPS. We have found that 4-HQN had a protective effect (30% survivor) when it was 
added 1 but not when it was added 6 hours after LPS injection suggesting that 4-HQN may 
interfere preferably with the early mediators of the effect of LPS (Fig. 1). To support these 
observations we studied some important late mediators of septic shock by Western blotting 
and found that LPS treatment did not affect the HMG-1 and COX-2 expression in lung, heart, 
small intestine, liver or spleen and PJ34 and 4-HQN did not have any additional effect on 
these factors (data not shown). It suggests that the beneficial effect of the post-treatment of 
PJ34 was evolving due a different mechanism. 
TNF-α is a substantial early mediator of endotoxemia since the production of this 
cytokine returned to a normal level 4 hours after LPS treatment (James PE 2002; Zanetti G 
1992). When administered before LPS treatment, both PARP-1 inhibitor attenuated the LPS-
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induced elevation in the serum TNF-α concentrations by approximately 50 % (Fig. 3), 
consistent with the notion that PJ34 and 4-HQN partially inhibits the expression of TNF-α 
gene. 
Due to the importance of the functional state of different organs during septic shock, 
we investigated in lung, liver and spleen various protein kinases that lead to transcription 
factor activation. Previous works had shown that LPS did induce activation of MAPK 
pathways in different cell lines, and it played key role in the transduction of the LPS signal 
between the extracellular receptor and the cytoplasmic and nuclear response resulting in 
activation of gene expression (Bozinovski et al., 2002; Dumitru et al., 2000). Furthermore, 
several papers showed that there is a cross-talk between ERK and other MAP kinases in 
different cell lines (Guha M 2002; Dumitru CD 2000; Xiao YQ 2002). In agreement with 
these results, we found that ERK and p38 MAPK had indeed a similar LPS-induced activation 
in lung but not in spleen and liver. In monocytes, macrophages and Tpl2 knockout mice, a 
functional association between ERK and JNK was reported that was not detectable in our 
BALB/c mice sepsis model. However, we have found that p90RSK, a downstream target of 
ERK, showed a similar activation pattern in lung as did ERK and p38 in response to the LPS 
treatment. The significance of this finding can be understood by considering that 
phosphorylated (i.e. activated) p90RSK can activate nuclear transcription factors such as c-
Fos and NF-κB. 
Since ERK is a key element of the signal transduction pathway that regulates the LPS-
mediated transcription factor activity, inhibition of this MAP kinase can contribute to 
reducing the endotoxin-induced inflammatory responses. Under our experimental conditions, 
ERK was activated by LPS in all the tissues studied (liver, lung and spleen) but p38 MAP 
kinase had detectable activation only in lung indicating that the signalling from cell surface 
CD14-TLR4/MD2 LPS receptor to the activation of the different branches of MAP kinases 
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has tissue specific components. Furthermore, we did not find detectable activation of JNK 
pathway that suggests that there is no functional association between either JNK pathway and 
cell surface LPS receptor or ERK and JNK pathways in these tissues in our experimental 
system. Interestingly, the phosphorylation of the ERK substrate p90RSK also showed tissue 
specificity (Fig. 6) indicating that ERK activation does not necessarily trigger the activation 
of p90RSK and the activation of p90RSK-dependent transcription factors. LPS induced the 
activation of ERK, p90RSK and p38 MAP kinase but not JNK in lung, and there was a 
significant increase in the activation of NF-κB and c-Fos transcription factors showing that 
gene expressions in lung are regulated by ERK or p38 MAP kinase but not by JNK pathway. 
In liver and spleen, out of the MAP kinases, only the ERK pathway was activated by LPS, 
and it is likely that this pathway activated the c-Fos and NF-κB transcription factors. In the 
absence of PARP-1 inhibitors, LPS did not affected PI-3-kinase/Akt pathway, therefore, MAP 
kinase pathways had to play the major role in activation of Ap-1 and NF-κB. 
When comparing the pattern of the activation and inhibition of the kinase cascades in 
the different organs of LPS or LPS + PARP-1 inhibitors treated mice, there was sometimes a 
poor correlation with the MRI data. One reason for this is that the hyperintensity in MRI 
signals due to inflammation and oedema originates from the intercellular space and not the 
organs themselves. Furthermore, by masking contrast, this hyperintensity makes the outlining 
of certain anatomical features within the field difficult or sometimes impossible. Thus, we 
found both the feasibility and relevance of such a comparison to be questionable. On the other 
hand, both the inflammatory response visualized by the MRI technique and the changes in the 
activities of the kinase cascades were clearly the result of the LPS treatment, and were 
attenuated by PARP-1 inhibitors. A more profound understanding of the events and 
mechanisms underlying LPS-induced septic shock could help to resolve this problem. 
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The most clear effect of PARP-1 inhibitors on the kinase cascades was the activation 
of Akt in the absence and in the presence of LPS in all studied tissues (Fig. 4). In monocytes, 
it was found that inhibition of PI-3-kinase/Akt pathway can activate MAP kinases (Guha M 
2002). Therefore, it is likely that activated Akt in the presence of PARP-1 inhibitor mediates 
the inhibition of MAP kinases and so the inhibition of NF-κB and AP-1 transcription factors 
resulting in inhibition of inflammatory gene expression. In conclusion, the most important 
protective effect of PARP-1 inhibitors in different organs can be the Akt activation and MAP 
kinase inhibition, and the inhibition of related transcription factors (Fig. 10). 
Since Akt activation can be induced by structurally different PARP-1 inhibitors, such 
as quinazoline derivatives, phenantridine derivatives and carboxamino benzimidazol 
derivatives (unpublished data), it is likely that this effect is related to the PARP-inhibitory 
property of these molecules, although, it is not clear how the inhibition of the nuclear PARP 
can activate cytoplasmic Akt. Furthermore, Luo et al. have recently showed in an other 
experimental model that PARP inhibitors prevent deactivation of Akt in N-methyl-D-
aspartate-induced neurotoxicity (Luo HR 2003). In spite of the lack of the precise molecular 
mechanism, the finding that PARP-1 inhibitors reverse the inflammatory processes and organ 
damages (Fig 2) probably via the activation one of the most important protective kinase 
cascade, the PI-3-kinase/Akt pathway, provide a novel possibility to prevent multiorgan 
failure in septic shock. While the Akt activation seems to occur in all studied tissues (Fig 4), 
the regulation of transcription factor activation appears to have some tissue specificity 
indicating that there are some tissue specific components between the MAP kinase pathway 
and the transcription factors regulated by this pathway. It can explain that Akt activation by 
PJ34 could supress NF-κB activation only in liver (Fig) and by 4-HQN in lung and in liver 
(Fig. 8), while c-Fos activation was suppressed by 4-HQN in all studied tissues (lung, liver, 
spleen) (Fig. 9). 
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Isoquinasolines such as 4-HQN and phenantridinons such as PJ34 inhibit PARP-1 
activity by competitive binding to the NAD binding site (Banasik M 1992; Jagtap P 2002). 
Thus, it is likely that all PARP isoforms are inhibited by PJ34 and 4-HQN since the catalytic 
site is highly conserved among the various PARP isoforms. In fact, no effects of these drugs 
on enzymes other than PARP have been reported. The high potency of the compound on 
PARP together with the fact that our findings on PJ34 and 4-HQN treated animals were very 
similar to those that were reported in PARP-1 deficient mice makes it likely that the principal 
action of the drugs were mediated via PARP inhibition. The various classes of recently 
emerging potent, non-toxic PARP inhibitors will help to further clarify this question.  
 
Fig. Schematic representation of the effect of 4-hydroxyquinazoline on Akt and MAPK 
activation, and NF-kappaB and Ap-1 activation. Binding of LPS to the CD14 and 
TLR4/MD2 complex activates the MAPK pathways. PARP-1 inhibitor directly or indirectly 
activates the PI3 kinase/Akt pathway and inactivates the ERK ½ and p38 MAPKs. Activation 
of Akt via PARP-1 inhibition can also inactivate these kinases. Inactivation of nuclear 
transcription factors (NF-κB, AP-1) is the consequence, at least partially, of the 
forementioned processes. 
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Taken together, our data show that LPS induces a different extent of MAP kinase 
activation in different organs, which can activate Ap-1 and NF-κB transcription factors in a 
tissue specific manner. Activation of these transcription factors induces activation of pro-
inflammatory genes that are most likely responsible for the tissue damages during septic 
shock. PARP-1 inhibitors beside their well-known effect of inhibiting NAD+ and ATP 
depletion, influence LPS-induced transcription factor activation and gene expression. These 
effects of PARP-1 inhibitors are mediated by the activation of PI-3-kinase/Akt pathway which 
can inhibit MAP kinase activation and can attenuate transcription factor activation and 
inflammatory tissue damage (Fig. 10) in a tissue specific manner. 
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